ISS recommends Infinity Pharma stockholders vote for MEI Pharma merger

Infinity Pharmaceuticals (INFI) announced that leading independent proxy advisor Institutional Shareholder Services has recommended that Infinity stockholders vote FOR the merger with MEI Pharma(MEIP) ISS is an independent proxy advisory firm whose clients include many of the world’s leading institutional investors, and who rely on ISS’s objective and impartial analysis to make important voting decisions. “We are pleased to receive ISS’s independent recommendation to Infinity stockholders to vote FOR the merger with MEI. The combined company will have an attractive combined clinical pipeline, strong balance sheet, and multiple value creation opportunities for stockholders. We believe stockholders will also benefit from an experienced and well-rounded management team with a strong focus in operational excellence to advance the development of our differentiated clinical candidates,” said Adelene Perkins, Chief Executive Officer, and Chair of Infinity’s board of directors.